Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype
- PMID: 22656670
- DOI: 10.1016/j.lungcan.2012.05.091
Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype
Abstract
Background: The differential therapeutic efficacy and toxicity of targeted therapies has made subtyping of non-small lung cancer (NSCLC) mandatory. This study aimed to review the accuracy of NSCLC subtyping using lung fine needle aspirates (FNAs) in two periods (before and after the introduction of targeted therapy), checking the reasons for failure and the impact of the use of immunohistochemistry (IHC).
Methods: An electronic search retrieved all NSCLC FNAs with a corresponding surgical specimen from 2001 to 2009. NSCLC, NOS (not otherwise specified) cases from 2005 to 2009 (after targeted therapy) were reviewed to determine reasons for failure in subtyping and to further subtype based solely on cytomorphology. The number of cases in which IHC was performed and the antibodies used were also recorded.
Results: Cytohistological agreement of 602 lung FNAs (341 adenocarcinomas, 93 squamous cell carcinomas and 168 NSCLC, NOS) was achieved in 93.80%. There was a significant decrease in the percentage of cases not subtyped in the period after the introduction of targeted therapy (35.07% versus 24.57%). Final percentage of cases not subtyped after morphological review was 17.03%. IHC was performed in 157 cases, with an increased use in recent years. The number of antibodies did not influence the overall success in subtyping and an average of 3 markers was used. Most frequent antibodies used were TTF-1, CK7, high molecular weight keratin and p63. More than half of cases not subtyped even after IHC corresponded to poorly or undifferentiated neoplasms in the surgical specimens. For the NSCLC, NOS which IHC was not performed, a cell block was produced in 106 cases (75.71%). Review of the cell block slides from 2005 to 2009 showed that the majority (70.7%) had rare, few or no tumor cells.
Conclusions: Specific subtyping can be achieved in a high proportion of lung FNAs with high accuracy. The percentage of NSCLC, NOS has significantly decreased in recent years together with a trend for an increased use of IHC as well as increased number of cell blocks produced. An average of 3 IHC markers was used for subtyping and the number of markers did not influence the overall subtyping.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.J Thorac Oncol. 2010 Apr;5(4):442-7. doi: 10.1097/JTO.0b013e3181d40fac. J Thorac Oncol. 2010. PMID: 20195168
-
Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation.Cancer. 2011 Aug 1;117(15):3416-23. doi: 10.1002/cncr.25830. Epub 2011 Jan 18. Cancer. 2011. PMID: 21246522
-
The utility of fine-needle aspiration in the diagnosis of primary and metastatic tumors to the lung: a retrospective examination of 1,032 cases.Acta Cytol. 2012;56(6):590-5. doi: 10.1159/000342935. Epub 2012 Nov 24. Acta Cytol. 2012. PMID: 23207436
-
Factors influencing a specific pathologic diagnosis of non-small-cell lung carcinoma.Clin Lung Cancer. 2013 May;14(3):238-44. doi: 10.1016/j.cllc.2012.11.004. Epub 2013 Jan 4. Clin Lung Cancer. 2013. PMID: 23291255 Review.
-
A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments.Int J Surg Pathol. 2009 Jun;17(3):206-18. doi: 10.1177/1066896909336178. Int J Surg Pathol. 2009. PMID: 19443885 Review.
Cited by
-
Diagnosing lung carcinomas with optical coherence tomography.Ann Am Thorac Soc. 2015 Feb;12(2):193-201. doi: 10.1513/AnnalsATS.201408-370OC. Ann Am Thorac Soc. 2015. PMID: 25562183 Free PMC article.
-
Novel image features of optical coherence tomography for pathological classification of lung cancer: Results from a prospective clinical trial.Front Oncol. 2022 Oct 21;12:870556. doi: 10.3389/fonc.2022.870556. eCollection 2022. Front Oncol. 2022. PMID: 36338729 Free PMC article.
-
The utility of cytology in the diagnosis of adenocarcinoma lung: A tertiary care center study.J Cytol. 2015 Jul-Sep;32(3):159-64. doi: 10.4103/0970-9371.168838. J Cytol. 2015. PMID: 26729975 Free PMC article.
-
Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care?Curr Oncol. 2015 Aug;22(4):272-8. doi: 10.3747/co.22.2526. Curr Oncol. 2015. PMID: 26300665 Free PMC article.
-
Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens.Arch Pathol Lab Med. 2016 Oct;140(10):1116-20. doi: 10.5858/arpa.2015-0316-OA. Epub 2016 Aug 23. Arch Pathol Lab Med. 2016. PMID: 27552093 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials